Bonuccelli Ubaldo, Ceravolo Roberto
University of Pisa, Department of Neuroscience, Via Roma, 67 56100 Pisa, Italy.
Expert Opin Drug Saf. 2008 Mar;7(2):111-27. doi: 10.1517/14740338.7.2.111.
Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease. These drugs have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients < 65-70 years old, because they are about as effective as levodopa, but patients demonstrate a lower tendency to develop motor complications. However, dopamine agonists could have peripheral and central side effects, which are often the reason for the discontinuation of the treatment. This review focuses on the potential negative effects related to the use of dopamine agonists in the treatment of Parkinson's disease.
多巴胺激动剂作为晚期帕金森病左旋多巴的辅助治疗非常有效。这些药物在帕金森病早期作为<65 - 70岁患者的单一疗法迅速受到欢迎，因为它们与左旋多巴的疗效相当，但患者出现运动并发症的倾向较低。然而，多巴胺激动剂可能会有外周和中枢副作用，这往往是治疗中断的原因。本综述重点关注与使用多巴胺激动剂治疗帕金森病相关的潜在负面影响。
